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We were very interested by the article by Nowakowski et al. 1 describing the combination of lenalidomide and R-CHOP in patients with aggressive lymphoma. Our group conducted a similar phase 1b study of this combination in a patient population with predominantly indolent B-cell lymphoma.
The primary objective of the study was to determine the recommended dose of lenalinomide administered for 14 days in association with standard 21-day R-CHOP (R2-CHOP). Dose of lenalidomide was assessed during the first two cycles. Secondary objectives were to assess the safety and efficacy of R2-CHOP for a maximum of six cycles.
Patients from 18 to 70 years of age had documented B-cell CD20-positive lymphoma: mantle cell lymphoma, marginal zone lymphoma, lymphocytic lymphoma, follicular lymphoma, diffuse large B-cell lymphoma or histological transformation from low grade to high grade lymphoma. Lenalidomide (5, 10, 15, 20 or 25 mg once daily) was escalated in serial patient cohorts using a standard 3 þ 3 design. Each cycle of R2-CHOP comprised the 2 of vincristine (up to a maximal dose of 2 mg, in 50-100 ml normal saline in 10-20 min i.v. infusion after cyclophosphamide) on day 1 and 60 mg/m 2 of prednisone on days 1 through 5. Pegfilgrastim was given at day 4 of each cycle at a dose of 6 mg. 2 Aspirin prophylaxis (100 mg daily) was mandatory during the study period. A prophylaxis of Pneumocystic jirovecii pneumonia was recommended during the study and until 3 months after last cycle administration. Dose escalation was determined by the number of dose limiting toxicities (DLTs) observed during the administration of the two first cycles of R2-CHOP. DLTs were defined as any grade 3-4 nonhematological toxicity, grade 3 neutropenia or thombocytopenia lasting more than 7 days, or grade 4 neutropenia or thombocytopenia lasting more than 3 days. Once maximal tolerated dose was reached, the cohort was expanded to a total of 12 patients. There was no individual dose adjustment of lenalidomide. If a patient experienced a DLT, lenalidomide treatment was definitively stopped and the patient continued on treatment with R-CHOP. There was no dose adjustment of R-CHOP in case of hematological toxicity or failure to recover neutrophil count of 1.5 Â 10 9 /l or platelet count o100 Â 10 9 /l at day 21, but the next cycle could be postponed for a maximum of 7 additional days (day 28). If grade 1 neurological toxicity was related to vincristine, the dose was reduced to 1 mg. If the neurological toxicity increased despite of dose reduction, vincristine was stopped.
All patients provided written informed consent. The study was approved by the Comité de Protection des Personnes Sud-Est II, Lyon, France and by the regulatory authorities. Clinical Trials.gov identifier NCT00901615.
Twenty-eight patients were enrolled in the study from January 2009 to June 2010. One patient did not receive any treatment and was excluded from analysis. Patient characteristics are summarized in Table 1 . Although the inclusion criteria limited the age to 70 years, a patient aged 77 years was included. The majority of patients had follicular lymphoma and the majority had disseminated disease.
DOSE ESCALATION
No DLTs occurred at lenalidomide dose of 5, 10 and 15 mg. One neutropenic grade 4 episode lasting more than 3 days occurred at the 20 mg level. One of six patients at the 25 mg level experienced a transient grade 3 hepatic toxicity in the course of the first cycle. As there was no intent to increase the lenalidomide dose above 25 mg, this dose was considered the recommended dose and the 25 mg cohort was expanded.
SAFETY AND TOLERABILITY
Lenalidomide was discontinued in six patients, three because of hematological toxicity (after two cycles in two patients and after four cycles in one patient), two for thrombosis (after three and four cycles, respectively) and one for hepatic toxicity at the first cycle. R2-CHOP was discontinued after the fifth cycle in one patient whose disease progressed. Lenalidomide was interrupted during 1-9 days in the course of six of the 143 cycles administered in five patients, mostly because of neutropenia. Six patients had cycle delays; five resulting from hematological toxicity and one resulting from bronchitis associated to chronic respiratory insufficiency.
Adverse events are shown in Table 2 . Grade 3 and 4 neutropenia occurred in 19% and 41% of patients, respectively. Two neutropenic patients experienced a grade 3 febrile episode. Grade 3 and 4 thrombocytopenia occurred in 26% and 4% of patients, respectively. One patient had propionibacterium acnes septicemia outside of a neutropenic phase. Two thrombosis episodes occurred despite aspirin prophylaxis. One patient, the one who was 77 years old, had a pulmonary embolism and recovered rapidly with anticoagulation therapy and one patient had a deep venous thrombosis related to the central catheter. Seven patients had a mild rash attributed to lenalidomide. We did not observe grade 3-4 neuropathy but nine patients experienced grade 1 and four patients had grade 2 sensory neuropathy. Two patients had vincristine discontinuation at cycle 4 and 6, respectively.
RESPONSE TO TREATMENT
Response according to lenalidomide dose is given in Supplemental Table 1 . The overall response rate was 96%, with 74% of patients achieving a complete remission (CR/CRu). Only one patient with disseminated follicular lymphoma had histological transformation with meningeal involvement after the fifth cycle.
DISCUSSION
Results of this 1b trial of the combination of R-CHOP and lenalidomide confirm the results from Nowakowski et al. 1 The toxicity profile was similar in the two studies resulting in infrequent discontinuation of lenalidomide and only few delays related to slow hematological recovery. Although primary prophylaxis with pegfiltrastim was used in both studies, the potentially lower incidence of grade 4 neutropenia in our study could be due to the administration of this drug on day 4 of the cycle. 2 With this policy, the rate of febrile neutropenia episodes after R2-CHOP did not appear to be more frequent than after R-CHOP. 3 Mild sensory neuropathy symptoms were observed in half of our patients leading to discontinuation of vincristine for the last cycles of the treatment in two patients. Similarly to Nowakowski et al., 1 we observed a thrombosis episode in two patients who were receiving aspirin prophylaxis. Lenalidomide was discontinued in both patients and symptoms resolved with anticoagulation. We agree that ongoing phase 2 trials will help better assessing the risk of thrombosis in patients treated with R2-CHOP.
A 14-day treatment with lenalidomide during each 21-day cycle, in our study, as compared with 10 days in the study from Nowakowski et al.,
1 results in longer exposure to lenalidomide and does not appear to increase the toxicity of the combination. Overall, both studies conclude that a daily dose of lenalidomide 25 mg appears to be safe in combination with R-CHOP and worth studying in phase 2.
There is a strong rationale to study the combination of lenalidomide and R-CHOP in follicular lymphoma. Although the mechanism of action of lenalidomide appears complex, several of its activities exhibit a potential interest in the treatment of B-cell lymphomas. 4 Lenalidomide has been shown to repair the defective immunological synapse between T cells and follicular lymphoma cells in vitro. 5 Results of an early phase II study in patients with refractory/relapsed indolent lymphoma have shown an overall response rate of 27% in the subgroup of patients with follicular lymphoma. 6 Furthermore, several studies have shown that lenalidomide has the potential to enhance natural killer cell activity, monocyte-mediated antibody-dependent cellular cytotocity and aptoptosis effect of rituximab on lymphoma B-cell lines. 7, 8 Recent clinical results demonstrate a remarkable efficacy of the combination of lenalidomide and rituximab in the frontline treatment of follicular lymphoma, which confirms this synergy. 9 Long-term follow-up of patients with follicular lymphoma has shown that quality of CR could be correlated to an improved survival. 10 It is then conceivable that the combination of lenalidomide with R-CHOP, currently the most effective treatment for follicular lymphoma, 11, 12 will increase the efficacy Letters to the Editor of immunochemotherapy. Our group is currently conducting a phase 2 trial to test this hypothesis in patients with high tumor burden follicular lymphoma. Although chronic lymphocytic leukemia (CLL) is characterized by a strong familial risk, the genetic basis of inherited susceptibility to CLL is largely unknown. The increased risk of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in relatives of CLL patients suggests a common etiology to B-cell lymphoproliferative disorders (LPDs) through HLA variation. 1 Moreover, as B-cell proliferation is part of an adaptive immune response, which can be initiated by major histocompatibility complex (MHC)-restricted T-cell activation, a possible influence of HLA on CLL pathogenesis is plausible.
CONFLICT OF INTEREST
It has recently been demonstrated that single nucleotide polymorphism (SNP) variation within the 6p21 region can accurately predict alleles at HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQA1 and HLA-DQB1 loci. 2 Furthermore, HLA alleles can be accurately predicted from the SNPs used in a genome-wide association study (GWAS). To investigate the role of genetic variation in the MHC region in the etiology of CLL, we have applied this methodology to SNP data from a GWAS of CLL.
The 517 CLL cases (364 male) analyzed in the GWAS have been previously documented. 3 Briefly, they comprised 155 CLL cases with a relative affected with CLL or a related B-cell LPD ascertained through the International CLL linkage consortium (ICLLLC) and 362 cases ascertained through the Leukemia Research CLL4 trial. The genome-wide SNP scan was conducted using Illumina Infinium HD Human370 Duo BeadChips. 3 For controls we made use of genotype data generated by the Wellcome Trust Case Control Consortium on 2930 individuals from the British 1958 Birth Cohort (58BC). Collection of samples and information from subjects was undertaken with informed consent and ethical review board approval. After imposing rigorous quality control in terms of excluding samples and SNPs with poor call rates and SNPs showing significant departure from Hardy-Weinberg equilibrium, samples showing evidence of relatedness and ancestral differences, 3 SNP genotypes were available on 503 cases and 2698 controls.
For single SNP and haplotype analysis we considered the MHC at 6p21 to be defined by a 5-Mb region bordered by the RFP and MLN genes (rs4324798 at 28 884 096 bp and rs767896 at 33 899 493 bp; Figure 1 ). We initially considered the 1149 SNPs mapping to this 5-Mb region analyzing the association between SNP and CLL using the Cochran-Armitage trend test. Odds ratios (ORs) and associated 95% confidence intervals (CIs) were calculated by unconditional logistic regression. At the 0.05 threshold, 88 SNPs showed evidence of an association compared with an expected of 57.5 (Po0.001). Associations at the 0.01 threshold are reported in Supplementary Table 1 . The strongest single association was shown by rs6904029, which maps at 30 051 046 bp localizing to the genomic sequence for the noncoding sequence for HLA complex group 9 that is intronic to HLA-A (P ¼ 1.38 Â 10 
